Stereotaxis, INC

Stereotaxis has finalized its acquisition of Robocath, integrating French robotic technology to enhance its surgical robotics offerings.

Stereotaxis, Inc. successfully concluded its 2026 Annual Meeting of Shareholders, confirming the election of three directors and the ratification of its independent auditor.

Stereotaxis announced its first quarter 2026 financial results, highlighting regulatory approvals for new products and a strategic acquisition, while revenue declined year-over-year.

Stereotaxis, Inc. announced its definitive agreement to acquire Robocath, a French robotic technology innovator, for an initial consideration of $20 million and potential earnout payments up to $25 million.

Stereotaxis reports Q3 2025 financial results, highlighting new robotic system orders, FDA clearance for GenesisX, and progress in its catheter portfolio.

Stereotaxis, Inc. has entered into a sales agreement with Roth Capital Partners, LLC to sell up to $50 million of common stock through an at-the-market offering.

Stereotaxis reports a 19% revenue decrease in Q3 2025, but a 15% increase year-to-date, driven by disposables, alongside key regulatory approvals and a $7.8 million equity raise.

Stereotaxis, Inc. reported a significant increase in second-quarter revenue driven by system sales and disposable products, alongside progress in regulatory approvals for its robotic navigation systems and catheters, despite ongoing net losses and macroeconomic headwinds.

Stereotaxis saw a revenue increase in Q1 2025, but continues to operate at a loss, with potential tariff implications looming.

Stereotaxis' Q3 2024 results show a revenue increase but also a net loss, influenced by the acquisition of Access Point Technologies EP, Inc. and ongoing market challenges.

Stereotaxis' Q2 2024 results show a decrease in revenue compared to the same period last year, alongside the completion of the acquisition of Access Point Technologies.

Stereotaxis, Inc. announced its first quarter 2024 financial results, showing a 5% increase in revenue compared to the same period last year, driven by higher system sales.

Stereotaxis, Inc. has filed an amendment to its 2025 Form 10-K to include auditor signatures and correct an exhibit number, with no changes to the original financial disclosures.

Stereotaxis, Inc. reported a 20% revenue increase in 2025, driven by system sales and disposable devices, alongside key regulatory approvals for new robotic navigation products, despite continued net losses.

Stereotaxis reports a marginal revenue increase in 2024, highlighting its acquisition of Access Point Technologies EP, Inc. and ongoing development of robotic systems and disposable devices.

Stereotaxis, Inc. reports a decrease in revenue for 2023, impacted by supply chain issues and macroeconomic factors, while highlighting growth in system sales.

Director Nachum Shamir of Stereotaxis, Inc. was granted 43,103 restricted share units on July 1, 2026, as part of his compensation.

Director David Benfer acquired 43,103 restricted share units in Stereotaxis, Inc. on July 1, 2026.

Director Ross B. Levin acquired 43,103 restricted share units of Stereotaxis, Inc. (STXS) on July 1, 2026.

Director Myriam Curet acquired 43,103 restricted share units of Stereotaxis, Inc. on July 1, 2026, as part of a grant.

Director Nathan Fischel acquired 43,103 restricted share units of Stereotaxis, Inc. on July 1, 2026, as part of a grant.

Arun Swarup Menawat, a Director at Stereotaxis, Inc., was granted 43,103 restricted share units on July 1, 2026.

Stereotaxis, Inc. has issued its proxy statement for the 2026 Annual Meeting of Shareholders, detailing proposals for director elections, auditor ratification, and executive compensation.

Stereotaxis, Inc. has filed a definitive proxy statement with the SEC in accordance with Section 14(a) of the Securities Exchange Act of 1934.

Stereotaxis, Inc. has scheduled its Annual Meeting of Shareholders for May 15, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Stereotaxis issues a supplement to its proxy statement clarifying that broker non-votes will not affect the outcome of votes on proposals to amend the 2022 Stock Incentive Plan and the Employee Stock Purchase Plan.

Stereotaxis, Inc. has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

Stereotaxis is asking shareholders to approve amendments to its stock incentive and employee stock purchase plans at the upcoming Annual Meeting of Shareholders on May 15, 2024.

Lagoda Investment Management, L.P. has filed a Schedule 13G, reporting a 5.1% beneficial ownership stake in medical technology company Stereotaxis, Inc. as of March 31, 2025.